Prospects for PARP inhibitor Lynparza (olaparib) were boosted when AstraZeneca PLC and partner Merck & Co. Inc. reported positive top-line results from the pivotal SOLO-1 trial testing the tablet as a first-line maintenance monotherapy in patients with BRCA-mutated advanced ovarian cancer following first-line platinum-based chemotherapy.
In the Phase III SOLO-1 study Lynparza showed "statistically significant and clinically meaningful improvement" in progression-free survival (PFS) versus placebo
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?